Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decline in Short Interest

Key Points

• Fresenius SE & Co. experienced a significant decline in short interest, dropping by 33.5% from 22,700 shares to 15,100 shares during July 2023.
• The company reported quarterly earnings of $0.24 per share, surpassing analyst expectations of $0.22, and had a revenue of $6.48 billion for the quarter.
• Fresenius SE & Co. announced a dividend increase, with a new dividend of $0.1827 per share reflecting a remarkable yield of 148.0%.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 15,100 shares, adeclineof33.5% from the July 15th total of 22,700 shares. Based on an average daily volume of 45,300 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 45,300 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy".

Fresenius SE & Co. Stock Up 1.7%

Shares of OTCMKTS:FSNUY traded up $0.23 during midday trading on Friday, hitting $14.10. The company's stock had a trading volume of 177,434 shares, compared to its average volume of 25,170. The company has a current ratio of 1.43, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock's 50 day simple moving average is $12.53 and its 200 day simple moving average is $11.64. Fresenius SE & Co. has a fifty-two week low of $8.4780 and a fifty-two week high of $14.20.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $6.48 billion during the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. As a group, equities analysts forecast that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.